UK Markets closed

MEDICLIN Aktiengesellschaft (0NDG.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
5.25-0.13 (-2.33%)
At close: 12:14PM GMT
Full screen
Previous close5.25
Open5.25
Bid0.00 x 0
Ask0.00 x 0
Day's range5.25 - 5.25
52-week range5.25 - 5.25
Volume5,000
Avg. volumeN/A
Market cap243.576M
Beta (5Y monthly)0.16
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • EQS Group

    MediClin AG: Dr. Joachim Ramming becomes the new CEO of MEDICLIN

    DGAP-News: MediClin AG / Key word(s): Personnel11.06.2021 / 12:41 The issuer is solely responsible for the content of this announcement.Dr. Joachim Ramming becomes the new CEO of MEDICLINIn today's meeting, the Supervisory Board of MEDICLIN Aktiengesellschaft (MEDICLIN) has appointed Dr. Joachim Ramming as member of the Management Board of MEDICLIN and as Chairman of the Board. The PhD economist and health economist will succeed Volker Hippler on August 1, 2021, who is resigning his mandate as C

  • EQS Group

    MEDICLIN focuses on patient safety and innovative concepts in rehabilitation

    DGAP-News: MediClin AG / Key word(s): AGM/EGM28.05.2021 / 09:26 The issuer is solely responsible for the content of this announcement.MEDICLIN focuses on patient safety and innovative concepts in rehabilitationAt the Annual General Meeting of MEDICLIN Aktiengesellschaft (MEDICLIN) held on May 26, 2021, Chairman of the Management Board Volker Hippler gave a mixed picture of the situation. After the focus of the health policy and legislative measures aimed at preventing an overload of the health system, MEDICLIN reacted quickly and professionally to the new requirements. "We have fulfilled our responsibility as a health care provider in dealing with the pandemic, even if this left its mark on our earning power in the 2020 financial year", said Volker Hippler, explaining the business development.Tino Fritz, Chief Financial Officer of MEDICLIN, commented on the current situation as follows in response to a shareholder question: "Of course we are working on getting the occupancy up again, but the sales and earnings development for the year as a whole will depend on the development of the pandemic and the level of protective shielding benefits. These will be much lower for the year 2021."Overall, the protective shield benefits decided by politicians and the payments from the cost providers, as in the 2020 financial year, only compensate for a small part of the capacity losses and the higher costs.Patient safety comes firstIn his speech, the CEO emphasized that the focus is on the health and thus the safety of patients and employees. The hygiene concepts work well, as do the treatment and therapy concepts under special corona-related requirements. The feedback on patient satisfaction confirms this for the Group.Competence in post-COVID and long-COVID treatmentsHe particularly highlighted the interdisciplinary expertise that MEDICLIN has in the treatment of post-COVID and long-COVID patients. Pneumology experts work closely with experts in neurology, cardiology, psychiatry and psychosomatics. MEDICLIN has so far treated successfully more than 1,250 corona patients, and demand has risen sharply.Innovative concepts in rehabilitationDr. York Dhein, Member of the Management Board of MEDICLIN and responsible for this business segment, explained the future requirements of a performance based rehabilitation. "It will be a particular challenge to adapt rehabilitation to the changing demographic and social requirements with innovative performance-based concepts," he said and added: "That we can quickly build up and implement knowledge in our company MEDICLIN has shown in the treatment of post- and long-COVID patients."Information on the Annual General MeetingAt the Annual General Meeting of MEDICLIN Aktiengesellschaft 91.81% of the share capital was represented.With a large majority of 96.81%, the Annual General Meeting passed a new remuneration system for the Management Board.The actions of the Board of Management and the Supervisory Board were approved for 2020 with majorities of 98.57% and 98.41%, respectively.Because of the pandemic, the event again took place virtually on the Internet to protect the health of all those involved.About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)MEDICLIN includes 35 clinics, seven care facilities and ten medical care centers. The Group has around 8,350 beds / care places and employs around 10,300 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.MEDICLIN ─ a Company of the Asklepios-Group.28.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: MediClin AG Okenstraße 27 77652 Offenburg Germany Phone: +49 (0)781 488-326 Fax: +49 (0)781 488-184 E-mail: alexandra.muehr@mediclin.de Internet: www.mediclin.de ISIN: DE0006595101 WKN: 659510 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1201934 End of News DGAP News Service

  • EQS Group

    MediClin AG: The effects of the coronavirus pandemic are burdening the business development in the first quarter of 2021

    DGAP-News: MediClin AG / Key word(s): Quarterly / Interim Statement03.05.2021 / 17:58 The issuer is solely responsible for the content of this announcement.The effects of the coronavirus pandemic are burdening the business development in the first quarter of 2021The economic and social effects of the coronavirus pandemic, i.e. lockdown, increasing capacity utilization in intensive care units, reserved capacities and postponed acute treatments, weighed on the business development of MEDICLIN Aktiengesellschaft (MEDICLIN) in the first quarter of the new financial year 2021.Group EBIT significantly below prior-year quarter despite cost reductions lIn the 1st quarter of 2021, Group sales amounted to EUR 156.4 mill. and were EUR 11.0 mill. or 6.6% below the value of the 1st quarter of 2020. Group sales include a total of EUR 7.6 mill. in protective shielding benefits for free capacities and payments on the part of the cost providers for additional expenses for hygiene and protective materials.Despite these benefits and a total of EUR 2.1 mill. lower expenses, the Group operating result was EUR -11.9 mill. and thus EUR 8.0 mill. below the value of the first quarter of 2020. Protective shield benefits and payments from the cost providers, which have been severely reduced by politicians, only accounted for a small part of the capacity losses and the higher costs", said Tino Fritz, CFO of MEDICLIN, commenting on the business development.Cash and cash equivalents as of 31 March 2021 amounted to EUR 100.1 mill. (31.12.2020: EUR 100.4 mill.). Cash and cash equivalents contain a total of about EUR 56.0 mill. in expected repayments to be made in the course of 2021, in particular of benefits under the protective shield previously received. Furthermore, the cash and cash equivalents item includes about EUR 18.0 mill. in subsidies for the planned construction of a new clinic.OutlookThe number of people infected with corona, which has been rising steadily since the beginning of February 2021, and the capacity bottlenecks in clinics with intensive care units, only allow a reliable estimate on the company's own business development based on experience gained in the previous year. "The sales and earnings development for the year as a whole depends largely on the development of the pandemic and the protective shielding benefits, which will be significantly lower in 2021 than in the previous year," said Volker Hippler, CEO of MEDICLIN.Currently, MEDICLIN assumes that occupancy rates at pre-Corona levels will not be achievable before the second half of the year 2021 as vaccinations are progressing only very slowly.The interim report for the first quarter of 2021 is available from today at https://www.mediclin.de/investor-relations/finanzpublikationen/ in German and English./About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)MEDICLIN includes 35 clinics, seven care facilities and ten medical care centers. The Group has around 8,350 beds / care places and employs around 10,300 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.MEDICLIN ─ ein Unternehmen der Asklepios-Gruppe.03.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: MediClin AG Okenstraße 27 77652 Offenburg Germany Phone: +49 (0)781 488-326 Fax: +49 (0)781 488-184 E-mail: alexandra.muehr@mediclin.de Internet: www.mediclin.de ISIN: DE0006595101 WKN: 659510 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1191921 End of News DGAP News Service